Episode Details
Back to Episodes
Ep 82: Best of ASCO: 2026
Season 2
Episode 82
Published 2 days, 10 hours ago
Description
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.
They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.
Studies discussed include:
- OptimUM-02 phase 2/3 trial for metastatic uveal melanoma
- ADAM phase 3 trial for MCC
- 5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)
- Pilot neoadjuvant studies (NeoReNi, NeoINR)
- Time of day of infusion and immunotherapy efficacy